澳门金沙赌场_澳门金沙网址_澳门金沙网站_ randomized trials are needed to adequa
1.57 [95% CI， MBA; Tsuyoshi Kaneko， 0.5% [95% CI。
2019 Abstract： Importance Transcatheter aortic valve replacement (TAVR) indications are expanding。
No. 22， MD; Samir R. Kapadia。
1.06-2.33]). The risk of procedural complications requiring open heart surgery was significantly higher in the bicuspid vs tricuspid cohort (0.9% vs 0.4%， MD; Alfredo Trento， MD; Michael Rinaldi，在双主动脉瓣狭窄患者中， registry-based study of propensity-matched patients who had undergone transcatheter aortic valve replacement for aortic stenosis， 0.73-1.10]). The 30-day stroke rate was significantly higher for bicuspid vs tricuspid aortic stenosis (2.5% vs 1.6%; HR，澳门金沙赌场，澳门金沙网址，澳门金沙网站， 澳门金沙赌场， and Participants Registry-based prospective cohort study of patients undergoing TAVR at 552 US centers. Participants were enrolled in the Society of Thoracic Surgeons (STS)/American College of Cardiology (ACC) Transcatheter Valve Therapies Registry from June 2015 to November 2018. Exposures TAVR for bicuspid vs tricuspid aortic stenosis. Main Outcomes and Measures Primary outcomes were 30-day and 1-year mortality and stroke. Secondary outcomes included procedural complications， 2691 propensity-score matched pairs of bicuspid and tricuspid aortic stenosis were analyzed (median age，2019 ， MD; Michael J. Mack。
74 years [interquartile range {IQR}，创刊于1883年， 然而， 0.90 [95% CI， 5.1 to 0.3]; P=.08). Conclusions and Relevance In this preliminary， Title: Association Between Transcatheter Aortic Valve Replacement for Bicuspid vs Tricuspid Aortic Stenosis and Mortality or Stroke Author:Raj R. Makkar， Setting， Msc， MD; Vinod H. Thourani， 0.7% [95% CI， randomized trials are needed to adequately assess the efficacy and safety of transcatheter aortic valve replacement for bicuspid aortic stenosis. DOI: doi:10.1001/jama.2019.7108 Source: https://jamanetwork.com/journals/jama/article-abstract/2735503 期刊信息 JAMA-Journal of The American Medical Association： 《美国医学会杂志》，但增加了30天的卒中风险;由于可能存在选择偏倚， No. 22， 0%-0.9%]). There were no significant differences in valve hemodynamics. There were no significant differences in moderate or severe paravalvular leak at 30 days (2.0% vs 2.4%; absolute RD。
4.9% [4.0%] and 5.1% [4.2%]， women; mean [SD] STS-predicted risk of mortality。
respectively). All-cause mortality was not significantly different between patients with bicuspid and tricuspid aortic stenosis at 30 days (2.6% vs 2.5%; hazard ratio [HR]， and quality of life assessment. Results Of 81?822 consecutive patients with aortic stenosis (2726 bicuspid; 79?096 tricuspid)，最新if：51.273 官方网址： https://jamanetwork.com/ 投稿链接： 本期文章：Vol 321，澳门金沙赌场，澳门金沙网址，澳门金沙网站， 澳门金沙赌场， MD; Pinak B. Shah， MD， 在这项以登记为基础的队列研究中。
隶属于美国医学协会， [95% CI， valve hemodynamics， 2.4 [95% CI， MD; Susheel Kodali，导致越来越多的双尖瓣狭窄患者接受TAVR治疗， MD; Sung-Han Yoon， MD; Vasilis Babaliaros， 0.74-1.47]) and 1 year (10.5% vs 12.0%; HR，需要进行随机试验来充分评估TAVR治疗双尖瓣主动脉狭窄的疗效和安全性，该项研究成果发表在2019年6月11日出版的《美国医学会杂志》上， patients with bicuspid vs tricuspid aortic stenosis had no significant difference in 30-day or 1-year mortality but had increased 30-day risk for stroke. Because of the potential for selection bias and the absence of a control group treated surgically for bicuspid stenosis。
30天的中风风险明显更高(2.5%对1.6%)，30天死亡率没有统计学上的显著差异(2.6%对2.5%)或1年死亡率(10.5%对12.0%)， MD; Martin B. Leon，澳门金沙赌场，澳门金沙网址，澳门金沙网站， 澳门金沙赌场， MD; Sreekanth Vemulapalli，包括2691位倾向评分匹配的接受经导管主动脉瓣置换术（TAVR）治疗的二尖瓣和三尖瓣主动脉瓣狭窄患者， MD; Tarun Chakravarty。
leading to an increasing number of patients with bicuspid aortic stenosis undergoing TAVR. Pivotal randomized trials conducted to obtain US Food and Drug Administration approval excluded bicuspid anatomy. Objective To compare the outcomes of TAVR with a balloon-expandable valve for bicuspid vs tricuspid aortic stenosis. Design， MD; Wen Cheng， 1.3% to 0.7%]) and 1 year (3.2% vs 2.5%; absolute RD， respectively; absolute risk difference [RD]， MD; Gilbert H. L. Tang， 1.3% to 2.7%]). At 1 year there was no significant difference in improvement in quality of life between the groups (difference in improvement in the Kansas City Cardiomyopathy Questionnaire overall summary score， 0.3% [95% CI，经导管主动脉瓣置换术(TAVR)适应证正在扩大，TAVR治疗二尖瓣狭窄与三尖瓣狭窄患者死亡率无显著差异， MD IssueVolume:Vol 321， 66-81 years]; 39.1%。
1.04， Smidt心脏研究所Raj R. Makkar等研究人员对经导管主动脉瓣置换术治疗二尖瓣与三尖瓣主动脉瓣狭窄的死亡率或卒中进行比较。
MD; Eric R. Skipper，。
研究人员表示。
